Mayhew Anna G, James Meredith K, Moore Ursula, Sutherland Helen, Jacobs Marni, Feng Jia, Lowes Linda Pax, Alfano Lindsay N, Muni Lofra Robert, Rufibach Laura E, Rose Kristy, Duong Tina, Bello Luca, Pedrosa-Hernández Irene, Holsten Scott, Sakamoto Chikako, Canal Aurélie, Sánchez-Aguilera Práxedes Nieves, Thiele Simone, Siener Catherine, Vandevelde Bruno, DeWolf Brittney, Maron Elke, Gordish-Dressman Heather, Hilsden Heather, Guglieri Michela, Hogrel Jean-Yves, Blamire Andrew M, Carlier Pierre G, Spuler Simone, Day John W, Jones Kristi J, Bharucha-Goebel Diana X, Salort-Campana Emmanuelle, Pestronk Alan, Walter Maggie C, Paradas Carmen, Stojkovic Tanya, Mori-Yoshimura Madoka, Bravver Elena, Díaz-Manera Jordi, Pegoraro Elena, Mendell Jerry R, Straub Volker
The John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.
Center for Translational Science, Division of Biostatistics and Study Methodology, Children's National Health System, Washington, DC, United States.
Front Neurol. 2022 Mar 10;13:828525. doi: 10.3389/fneur.2022.828525. eCollection 2022.
Dysferlinopathy is a muscular dystrophy with a highly variable functional disease progression in which the relationship of function to some patient reported outcome measures (PROMs) has not been previously reported. This analysis aims to identify the suitability of PROMs and their association with motor performance.Two-hundred and four patients with dysferlinopathy were identified in the Jain Foundation's Clinical Outcome Study in Dysferlinopathy from 14 sites in 8 countries. All patients completed the following PROMs: Individualized Neuromuscular Quality of Life Questionnaire (INQoL), International Physical Activity Questionnaire (IPAQ), and activity limitations for patients with upper and/or lower limb impairments (ACTIVLIMs). In addition, nonambulant patients completed the Egen Klassifikation Scale (EK). Assessments were conducted annually at baseline, years 1, 2, 3, and 4. Data were also collected on the North Star Assessment for Limb Girdle Type Muscular Dystrophies (NSAD) and Performance of Upper Limb (PUL) at these time points from year 2. Data were analyzed using descriptive statistics and Rasch analysis was conducted on ACTIVLIM, EK, INQoL. For associations, graphs (NSAD with ACTIVLIM, IPAQ and INQoL and EK with PUL) were generated from generalized estimating equations (GEE). The ACTIVLIM appeared robust psychometrically and was strongly associated with the NSAD total score (Pseudo 0.68). The INQoL performed less well and was poorly associated with the NSAD total score (Pseudo 0.18). EK scores were strongly associated with PUL (Pseudo 0.69). IPAQ was poorly associated with NSAD scores (Pseudo 0.09). This study showed that several of the chosen PROMs demonstrated change over time and a good association with functional outcomes. An alternative quality of life measure and method of collecting data on physical activity may need to be selected for assessing dysferlinopathy.
肌膜蛋白病是一种肌肉萎缩症,其功能疾病进展高度可变,此前尚未报道过功能与一些患者报告结局指标(PROMs)之间的关系。本分析旨在确定PROMs的适用性及其与运动表现的关联。在 Jain 基金会开展的一项针对肌膜蛋白病的临床结局研究中,从8个国家的14个地点识别出了204例肌膜蛋白病患者。所有患者均完成了以下PROMs:个性化神经肌肉生活质量问卷(INQoL)、国际体力活动问卷(IPAQ)以及上肢和/或下肢损伤患者的活动受限情况(ACTIVLIMs)。此外,非步行患者完成了埃根分类量表(EK)。在基线、第1年、第2年、第3年和第4年每年进行评估。在第2年及以后的这些时间点,还收集了关于肢带型肌肉萎缩症的北极星评估(NSAD)和上肢功能(PUL)的数据。使用描述性统计方法对数据进行分析,并对ACTIVLIM、EK、INQoL进行拉施分析。对于关联性分析,通过广义估计方程(GEE)生成图表(NSAD与ACTIVLIM、IPAQ和INQoL以及EK与PUL)。ACTIVLIM在心理测量学上表现稳健,且与NSAD总分密切相关(伪R 0.68)。INQoL表现较差,与NSAD总分的关联性较弱(伪R 0.18)。EK评分与PUL密切相关(伪R 0.69)。IPAQ与NSAD评分的关联性较弱(伪R 0.09)。本研究表明,所选用的几种PROMs随时间推移呈现出变化,且与功能结局具有良好的关联性。可能需要选择另一种生活质量测量方法和收集体力活动数据的方法来评估肌膜蛋白病。